<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971763</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000644293</org_study_id>
    <secondary_id>UCL/05/154</secondary_id>
    <secondary_id>2005-003888-23</secondary_id>
    <secondary_id>EU-20951</secondary_id>
    <nct_id>NCT00971763</nct_id>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase II Multicentre Trial of Gemcitabine, CVP, and Rituximab (R-GCVP) for the Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma, Considered Unsuitable for R-CHOP Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, cyclophosphamide,&#xD;
      vincristine sulfate, and prednisolone, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,&#xD;
      such as rituximab, can block cancer growth in different ways. Some block the ability of&#xD;
      cancer cells to grow and spread. Others find cancer cells and help kill them or carry&#xD;
      cancer-killing substances to them. Giving more than one drug (combination chemotherapy)&#xD;
      together with rituximab may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying giving gemcitabine hydrochloride, cyclophosphamide,&#xD;
      vincristine sulfate, and prednisolone together with rituximab to see how well it works in&#xD;
      treating patients with newly diagnosed diffuse large B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine whether rituximab, in combination with non-cardiotoxic chemotherapy&#xD;
           comprising gemcitabine hydrochloride, cyclophosphamide, vincristine sulfate, and&#xD;
           prednisolone, is efficacious in a group of patients who are unfit for CHOP chemotherapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8;&#xD;
      cyclophosphamide IV, vincristine sulfate IV, and rituximab IV on day 1; and oral prednisolone&#xD;
      once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 4&#xD;
      months for 1 year, and then every 6 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>End of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Not specified in protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Not specified in protocol</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-GCVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 6 x 21 day cycles of R-GCVP:&#xD;
Gemcitabine 750mg/m^2 days 1 &amp; 8 (increasing to 875mg/m^2 for cycle 2 &amp; 1g/m^2 for subsequent cycles if tolerated satisfactorily)&#xD;
Cyclophosphamide 750mg/m^2 day 1&#xD;
Vincristine 1.4mg/m^2 day 1 (capped at 2mg)&#xD;
Prednisolone 100mg/day days 1-5&#xD;
Rituximab 375mg/m^2 day 1&#xD;
Neulasta 6mg day 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>R-GCVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>R-GCVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>R-GCVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>R-GCVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>R-GCVP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed CD20-positive diffuse large B-cell non-Hodgkin lymphoma&#xD;
             (DLBCL) according to the current WHO classification, including all morphological&#xD;
             variants&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Bulky stage IA-IV disease&#xD;
&#xD;
                    -  No non-bulky stage IA disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Not eligible for CHOP chemotherapy due to impaired cardiac function&#xD;
&#xD;
               -  Cardiac status that does not allow the administration of 8 courses of R-CHOP&#xD;
                  chemotherapy, as defined by 1 of the following criteria:&#xD;
&#xD;
                    -  Ejection fraction less than 50% as assessed by either ECHO or MUGA scan&#xD;
&#xD;
                    -  NYHA class III-IV&#xD;
&#xD;
          -  No high-grade transformation of low-grade lymphoma&#xD;
&#xD;
          -  No symptomatic central nervous system or meningeal involvement by the lymphoma&#xD;
&#xD;
          -  No AIDS-related lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Platelet count &gt; 100 x 10^9/L&#xD;
&#xD;
          -  WBC &gt; 3 x 10^9/L&#xD;
&#xD;
          -  Neutrophils &gt; 1.5 x 10^9/L (unless elevated level attributed to bone marrow&#xD;
             infiltration by lymphoma)&#xD;
&#xD;
          -  Serum bilirubin &lt; 50 Î¼mol/L&#xD;
&#xD;
          -  Transaminases &lt; 2.5 times upper limit of normal (unless elevated level attributed to&#xD;
             lymphoma)&#xD;
&#xD;
          -  Glomerular filtration rate &gt; 30 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent uncontrolled medical condition&#xD;
&#xD;
          -  No active malignant disease, other than non-melanotic skin cancer or carcinoma in situ&#xD;
             of the uterine cervix, within the past 10 years&#xD;
&#xD;
          -  No positive serology for HIV&#xD;
&#xD;
          -  No medical or psychiatric conditions that compromise the patient's ability to give&#xD;
             informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy, radiotherapy, or other investigational drug for this indication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Fields, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Research UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sussex Cancer Centre at Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>England</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK and University College London Cancer Trials Centre</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

